The remission status of AML patients post alloSCT is associated with a distinct single-cell bone marrow T cell signature

Acute myeloid leukemia (AML) is a hematologic malignancy for which allogeneic stem cell transplantation (alloSCT) often remains the only curative therapeutic approach. However, incapability of T cells to recognize and eliminate residual leukemia stem cells (LSCs) might lead to an insufficient graft-versus-leukemia (GvL) effect and relapse. Here, we performed single-cell RNA-sequencing on bone marrow (BM) T lymphocytes and CD34+ cells of six AML patients 100 days after alloSCT to identify T …